February 5, 2015
For Immediate Release
Urologix Reports Second Quarter Fiscal Year 2015 Results
Recent Quarter Highlights
Revenue $3.1 Million, 2% increase from first quarter fiscal year 2015.
Net loss reduced by 67% to $357,000 from a net loss of $1.1 million in the second quarter of fiscal year 2014 and 18% lower than first quarter net loss of $437,000.
Total cash balances, including restricted cash, increased $25,000 compared to first quarter fiscal year 2015 ending cash balances.
MINNEAPOLIS — February 5, 2015— Urologix, Inc. (OTCQB: ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal year 2015 second quarter ended December 31, 2014.
Second quarter revenue totaled $3.1 million, an increase of 2% sequentially from the first quarter of fiscal year 2015 and down 19% compared to the second quarter of the prior fiscal year 2014. The sequential increase in revenue was driven by an increase in Cooled ThermoTherapy system sales and Prostiva® procedure kit sales. The Company experienced a 19% year over year decline in revenue which was driven by a decline in procedure kit sales in both product lines which was partially due to changes in the distribution model. The second quarter of prior fiscal year 2014 was the last full quarter before the restructuring of the Company began and we transitioned to a new distribution model in the second half of fiscal year 2014.
“We are pleased with the revenue achievement and the positive impact on our cash balances in the second quarter of fiscal year 2015. Achieving these goals is a big step for the Company as we work to build a stronger business with our new organizational structure that we implemented only eight months ago,” stated Greg Fluet, Chief Executive Officer. “Our continued focus on execution should enable achieving our primary goals to end fiscal year 2015 with positive cash flow from operations and to build upon the evidence demonstrating the cost-effectiveness of our in-office BPH technologies. The second quarter demonstrates major progress towards the first goal and we continue to drive towards achieving the second.”
Total operating expense was $1.6 million for the second quarter of fiscal year 2015, a 41% reduction compared to $2.7 million of operating expense for the second quarter of fiscal year 2014. The decrease in operating expenses compared to the prior year period is primarily a result of the 57% reduction in sales and marketing expense associated with the strategic reorganization the Company implemented in the latter half of fiscal year 2014. Operating expenses were comparable to the first quarter of fiscal year 2015, which were $1.7 million.


The Company reduced its net loss by 67% to a net loss of $357,000, or $0.02 per diluted share, for the second quarter of fiscal year 2015, compared to a net loss of $1.1 million, or $0.05 per diluted share, in the second quarter of fiscal year 2014. The net loss per diluted share was consistent with the first quarter of fiscal year 2015, which was also $0.02 per diluted share.
As of December 31, 2014, the Company’s cash balances totaled $570,000, including $40,000 of restricted cash, compared to $545,000 as of September 30, 2014, resulting in cash generation of $25,000 for the quarter. This positive increase in our cash balances compares to a decrease in the second quarter of the prior year of $284,000. The significant improvement in our cash utilization compared to the prior year was driven by the positive impact of our previously discussed organizational changes at the end of the 2014 fiscal year. Our cash utilization in the second quarter of both fiscal years 2014 and 2015 benefited from not paying the annual royalty and license amounts for the Prostiva products in those periods.
The Company’s cash needs will be determined by a number of items including its operating performance and the timing of payments associated with the Prostiva license due and unpaid and future payments due to Medtronic under the promissory note. The first payment of $1.3 million on the promissory note is due March 31, 2015. Royalty payments and other fees due and unpaid to Medtronic totaled $1.5 million as of December 31, 2014. Royalty payments currently due and unpaid are included in short- term deferred acquisition payments under current liabilities as of December 31, 2014.
The gross margin rate has remained consistent, with gross profit for the second quarter of fiscal year 2015 of $1.5 million, or 48% of revenue, compared to $1.8 million, or 47% of revenue, in the second quarter of fiscal year 2014, and $1.5 million, or 48% of revenue, in the first quarter of fiscal year 2015.
Earnings Call Information
Urologix will host a conference call with the financial community to discuss fiscal year 2015 second quarter results on Thursday, February 5, 2015 at 4:00 p.m. CST. To listen to the call, please dial 1-866-515-2910 and enter the Participant Passcode 37953871 at least 10 minutes prior to the call. A live webcast of the call will be available through the investor relations section of the Company’s website at www.urologix.com and available for replay approximately two hours after the completion of the call.


About Urologix
Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’s Cooled ThermoTherapy produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.
If you’d like more information on this topic, please contact Greg Fluet at (763) 475-1400 or investor-relations@urologix.com or to learn more about Urologix and its products and services, visit their website at www.urologix.com.
The Urologix, Inc. logo is available at www.urologix.com/clinicians/resource-library.php.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. Such forward looking statements include, for example, the effectiveness of the Company’s sales and marketing strategies and the impact of the Company’s strategic restructurings, the Company’s future revenue and operating performance, or about the development and marketing of products. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2014 and other documents filed with the Securities and Exchange Commission.
Urologix Media Contact
Urologix Investor Relations Contact
Susan Overby
Greg Fluet
(763) 745-1540
(763) 475-1400


Urologix, Inc.
Statements of Operations
(Unaudited, in thousands, except per share data)
Three Months Ended
December 31,
Six Months Ended
December 31,
  $ 3,079     $ 3,806     $ 6,100     $ 7,585  
Cost of goods sold
    1,615       2,008       3,174       3,923  
Gross profit
    1,464       1,798       2,926       3,662  
Costs and expenses:
Sales and marketing
    729       1,681       1,539       3,527  
General and administrative
    467       561       955       1,246  
Research and development
    337       452       671       874  
Change in value of acquisition consideration
          (85 )           (93 )
Medical device tax
    48       59       96       119  
Amortization expense
    17       22       40       44  
Total costs and expenses
    1,598       2,690       3,301       5,717  
Operating loss
    (134 )     (892 )     (375 )     (2,055 )
Interest expense
    (216 )     (178 )     (404 )     (338 )
Foreign currency exchange gain/(loss)
    (3 )     1       (6 )     2  
Loss before income taxes
    (353 )     (1,069 )     (785 )     (2,391 )
Income tax expense
    4       16       9       28  
Net loss
  $ (357 )   $ (1,085 )   $ (794 )   $ (2,419 )
Net loss per common share--basic
  $ (0.02 )   $ (0.05 )   $ (0.04 )   $ (0.11 )
Net loss per common share--diluted
  $ (0.02 )   $ (0.05 )   $ (0.04 )   $ (0.11 )
Weighted average number of common shares outstanding--basic
    21,782       21,245       21,634       21,132  
Weighted average number of common shares outstanding--diluted
    21,782       21,245       21,634       21,132  


Urologix, Inc.
Balance Sheets
( in thousands)
December 31,
June 30, 2014
Current assets:
  $ 530     $ 718  
Restricted cash
Accounts receivable, net
    1,488       1,502  
    1,323       1,397  
Prepaids and other current assets
    209       63  
Total current assets
    3,590       3,680  
Property and equipment:
Property and equipment
    12,120       12,162  
Less accumulated depreciation
    (11,792 )     (11,691 )
Property and equipment, net
    328       471  
Other intangible assets, net
    1,279       1,370  
Long-term inventories
    119       141  
Other assets
    5       5  
Total assets
  $ 5,321     $ 5,667  
Current liabilities:
Accounts payable
  $ 934     $ 892  
Accrued compensation
    364       487  
Short-term deferred acquisition payment
    1,997       1,339  
Current portion of long-term debt
    747       747  
Interest payable
    534       322  
Other accrued expenses
    542       505  
Total current liabilities
    5,118       4,292  
Long-term deferred acquisition payment
    3,333       3,730  
Long-term debt
    4,586       4,586  
Other accrued liabilities
    18       36  
Total liabilities
    13,055       12,644  
Shareholders’ deficit:
Common stock
    213       209  
Additional paid-in capital
    119,473       119,440  
Accumulated deficit
    (127,420 )     (126,626 )
Total shareholders’ deficit
    (7,734 )     (6,977 )
Total liabilities and shareholders’ deficit
  $ 5,321     $ 5,667  


Urologix, Inc.
Condensed Statements of Cash Flows
(Unaudited, in thousands)
Six Months Ended
December 31,
Operating Activities:
Net loss
  $ (794 )   $ (2,419 )
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization
    250       302  
Employee stock-based compensation expense
    37       122  
Provision for bad debts
    18       29  
Loss on disposal of assets
    2       3  
Accretion expense on deferred acquisition payments
    261       209  
Net adjustment to acquisition consideration
          (93 )
Deferred income taxes
Change in operating assets and liabilities:
Accounts receivable
    (4 )     247  
    88       276  
Prepaids and other assets
    (146 )     (136 )
Accounts payable
    42       426  
Other accrued expenses
    (104 )     (139 )
Interest payable
    212       165  
Net cash used for operating activities
    (138 )     (990 )
Investing Activities:
Purchases of property and equipment
    (1 )     (27 )
 Purchases of intellectual property
    (14 )     (6 )
 Proceeds from sale of property and equipment
 Cash restricted for collateral
    (40 )      
Net cash used for investing activities
    (50 )     (33 )
Net decrease in cash
    (188 )     (1,023 )
Beginning of period
    718       2,290  
End of period
  $ 530     $ 1,267  
Supplemental cash-flow information
Income taxes paid during the period
  $ 8     $ 12  
Net amount of inventory transferred to property and equipment
  $ 8     $ 22  



The following information was filed by Urologix Inc (ULGX) on Friday, February 6, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Urologix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Urologix Inc.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account